Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Cut by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 45.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,404 shares of the biopharmaceutical company’s stock after selling 1,158 shares during the period. Miracle Mile Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,000,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of REGN. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $37,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $39,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $39,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,032.57.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $690.87 on Wednesday. The firm has a market cap of $75.92 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. The stock’s 50-day moving average is $746.43 and its 200-day moving average is $956.18. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.